AtriCure Inc
NASDAQ:ATRC

Watchlist Manager
AtriCure Inc Logo
AtriCure Inc
NASDAQ:ATRC
Watchlist
Price: 30.75 USD 0.82% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
AtriCure Inc?
Write Note

AtriCure Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

AtriCure Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
AtriCure Inc
NASDAQ:ATRC
Accounts Payable
$103.5m
CAGR 3-Years
81%
CAGR 5-Years
49%
CAGR 10-Years
29%
Becton Dickinson and Co
NYSE:BDX
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Accounts Payable
$907m
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
15%
Stryker Corp
NYSE:SYK
Accounts Payable
$1.3B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
15%
Abbott Laboratories
NYSE:ABT
Accounts Payable
$4B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
15%
Intuitive Surgical Inc
NASDAQ:ISRG
Accounts Payable
$218.7m
CAGR 3-Years
22%
CAGR 5-Years
11%
CAGR 10-Years
15%
No Stocks Found

AtriCure Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Nestled in the heart of the highly competitive medical device industry, AtriCure Inc. has carved a significant niche for itself by focusing on the surgical treatment of atrial fibrillation, a common and potentially serious heart rhythm disorder. Founded in 2000 and headquartered in Mason, Ohio, AtriCure designs, manufactures, and sells an array of surgical devices aimed at improving treatment outcomes for this condition. The company’s innovative technology targets the complex network of electrical signals in the heart to restore regular rhythm and mitigate the risk of stroke—a common consequence of untreated atrial fibrillation. By providing surgeons with minimally invasive tools and advanced cryoablation and radiofrequency therapy systems, AtriCure not only addresses surgical efficiency but also enhances patient recovery times, distinguishing itself from its competitors. AtriCure derives its revenue from the sale of these sophisticated products directly to hospitals and surgical centers both in the United States and internationally. Key components of its portfolio include the Synergy Ablation System, which is acclaimed for its precision in creating lesions that block erratic electrical pathways, and AtriClip, a line of devices designed to occlude the left atrial appendage, thereby reducing stroke risk. As healthcare providers increasingly recognize the benefits of surgical intervention for atrial fibrillation over alternative treatments, AtriCure's financial health is buoyed by the rising adoption of its products. The company's strategic focus on expanding its product pipeline and enhancing its global sales footprint underscores its commitment to continuous growth and innovation in cardiac care.

ATRC Intrinsic Value
51 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is AtriCure Inc's Accounts Payable?
Accounts Payable
103.5m USD

Based on the financial report for Sep 30, 2024, AtriCure Inc's Accounts Payable amounts to 103.5m USD.

What is AtriCure Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
29%

Over the last year, the Accounts Payable growth was 322%. The average annual Accounts Payable growth rates for AtriCure Inc have been 81% over the past three years , 49% over the past five years , and 29% over the past ten years .

Back to Top